Table 3 Medications used by COVID-19 patients with dementia and matched controls without dementia during hospitalisation
Variables | Dementia N = 4051 | Control patientsa N = 1,1511 | p-value2 |
|---|---|---|---|
Anticoagulants | 294 (72.6%) | 882 (76.8%) | 0.106 |
Antibiotics during acute phase of COVID-19 | 294 (72.6%) | 872 (75.8%) | 0.231 |
Antibiotics for nosocomial infection | 277 (68.4%) | 795 (69.2%) | 0.814 |
Corticoids | 276 (68.1%) | 888 (77.3%) | < 0.001 |
Vasoactive amines | 90 (22.2%) | 410 (35.6%) | < 0.001 |
Oseltamivir | 77 (32.1%) | 231 (34.7%) | 0.507 |
Nonsteroidal anti-inflammatory drugs | 29 (18.8%) | 53 (12.5%) | 0.075 |
Inhaled corticoids | 24 (14.5%) | 78 (16.1%) | 0.723 |
Statin | 21 (13.6%) | 61 (14.4%) | 0.917 |
Antiarrhythmic | 10 (6.5%) | 47 (11.1%) | 0.137 |
Antifungal | 10 (3.1%) | 46 (5.1%) | 0.204 |
Hydroxychloroquine | 9 (5.8%) | 31 (7.3%) | 0.663 |
Neuromuscular-blocking drug (except for intubation) | 8 (4.8%) | 54 (11.2%) | 0.026 |
Clarithromycin | 7 (4.5%) | 22 (5.2%) | 0.918 |
Convalescent plasma | 2 (0.6%) | 11 (1.2%) | 0.533 |
Chloroquine | 0 (0.0%) | 0.122 | |
Tocilizumab | 0 (0.0%) | 7 (0.8%) | 0.200 |
Immunoglobulins | 0 (0.0%) | 4 (0.3%) | 0.578 |
Interferon | 0 (0.0%) | 2 (0.5%) | > 0.999 |
Remdesivir | 0 (0.0%) | 1 (0.1%) | > 0.999 |
Favipiravir | 0 (0.0%) | 0 (0.0%) | |
Ritonavir/Lopinavir | 0 (0.0%) | 0 (0.0%) | |
Umifenovir | 0 (0.0%) | 0 (0.0%) | |
Other specific therapy instituted for COVID-19 | 21 (6.6%) | 73 (8.0%) | 0.475 |
No specific therapy instituted for COVID-19 | 86 (27.0%) | 215 (23.7%) | 0.269 |